Actemra – Tocilizumab Injection

Actemra – Tocilizumab Injection
Actemra (tocilizumab) is a humanized anti IL-6 receptor monoclonal antibody. It binds specifically to IL-6 receptors. IL-6 is a pro-inflammatory cytokine produced by a variety of cell types, including T- and B-cells, lymphocytes, monocytes and fibroblasts.
Actemra is specifically indicated for the treatment of active systemic juvenile idiopathic arthritis in patients two years of age and older.

Actemra is supplied as a solution for intravenous infusion. The recommended dose for patients with systemic juvenile idiopathic arthritis is as follows:
patients less than 30 kg weight: 12 mg per kg once every two weeks as a 60-minute single intravenous drip infusion
patients at or above 30 kg weight: 8 mg per kg once every two weeks as a 60-minute single intravenous drip infusion.